MBRX vs SNDX vs IMVT vs AGIO vs TPVG

For growth investors, Syndax Pharmaceuticals, Inc.

(SNDX) is the stronger pick with 627. 8% revenue growth year-over-year, versus 36. 6% for TriplePoint Venture Growth BDC Corp. (TPVG). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Moleculin Biotech, Inc. (MBRX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -95. 0% for Moleculin Biotech, Inc. (MBRX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus MBRX's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Syndax Pharmaceuticals, Inc.

(SNDX) is the lower-risk stock at 0. 81β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 70% more volatile than SNDX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Syndax Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Syndax Pharmaceuticals, Inc.

(SNDX) is pulling ahead at 627. 8% versus 36. 6% for TriplePoint Venture Growth BDC Corp. (TPVG). On earnings-per-share growth, the picture is similar: Moleculin Biotech, Inc. grew EPS 82. 0% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — SNDX leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SNDX: 94.

7% to $40. 00.

In this comparison, TPVG (17.

1% yield), MBRX (0. 4% yield) pay a dividend. SNDX, IMVT, AGIO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 17. 1% yield). Both have compounded well over 10 years (TPVG: +93. 3%, MBRX: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MBRX (Healthcare) and SNDX (Healthcare) and IMVT (Healthcare) and AGIO (Healthcare) and TPVG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MBRX is a small-cap quality compounder stock; SNDX is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; TPVG is a small-cap high-growth stock. TPVG pays a dividend while MBRX, SNDX, IMVT, AGIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.